SCHEMBL2074591

SCHEMBL2074591

CN1CC[C@H](Oc2cc(Oc3ccc(C(=O)N4CCC4)cc3)cc(C(=O)O)c2)C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 7/20 0.48
KCNH2 Q12809 5/20 0.47
PRSS1 P07477 3/20 0.45
PRSS2 P07478 3/20 0.45
PRSS3 P35030 3/20 0.45
HTT P42858 1/20 0.42
MMP2 P08253 3/20 0.42
MMP9 P14780 3/20 0.42
HRH3 Q9Y5N1 2/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42
HPGD P15428 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 1/20 0.41
F2 P00734 2/20 0.41
ST14 Q9Y5Y6 2/20 0.41
PLG P00747 1/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2657926 0.90 GCK (0.49) GCKKCNH2PRSS1PRSS2PRSS3
SCHEMBL2072002 0.90 GCK (0.49) GCKKCNH2PRSS1PRSS2PRSS3
SCHEMBL2075334 0.86 HRH3 (0.48) GCKKCNH2HRH3
SCHEMBL2073632 0.82 GCK (0.56) GCKKCNH2
SCHEMBL2072154 0.82 GCK (0.62) GCKKCNH2
SCHEMBL2657879 0.81 GCK (0.65) GCKKCNH2
SCHEMBL2074921 0.81 GCK (0.65) GCKKCNH2
SCHEMBL2075828 0.81 GCK (0.46) GCKKCNH2HRH3
SCHEMBL2075320 0.81 GCK (0.46) GCKKCNH2HRH3
SCHEMBL2076122 0.81 GCK (0.46) GCKKCNH2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902200-B2 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity ASTRAZENECA AB (SE) 2011-03-08 US disclosed
US-7902200-B2 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity ASTRAZENECA AB (SE) 2011-03-08 US disclosed
US-7902200-B2 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity ASTRAZENECA AB (SE) 2011-03-08 US disclosed
US-20080171734-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-07-17 US disclosed
US-20080171734-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-07-17 US disclosed
US-20080171734-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-07-17 US disclosed
WO-2008050101-A2 BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK ASTRAZENECA AB (SE) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171734-A1 CHEMICAL COMPOUNDS HK1, GCKR, GCK GCK 3/4885KCNH2 1008/4885PRSS1 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.